Direct answer. Hepatitis B is a liver infection caused by HBV. It can clear after an acute infection or persist as chronic disease, sometimes without symptoms. Blood tests identify the infection and its phase; further assessment informs monitoring and antiviral treatment. Recent exposure, pregnancy and medicines that suppress immunity need particular planning. NHS November 2025 explanation.
- Feeling well does not rule out hepatitis B or the need for follow-up.
- Surface antigen, surface antibody and core antibody answer different testing questions.
- A chronic diagnosis does not automatically mean the same prescription for every person.
- Previous infection can matter before chemotherapy, immune treatment or hepatitis C treatment.
- An exposed person or a pregnancy needs prompt, locally appropriate prevention advice.
- Supplements are not an independently established replacement for HBV care.
Table of contents
- Evidence summary
- Acute hepatitis B, chronic infection and silent disease
- Blood, body-fluid and birth-related transmission
- Supportive care, antiviral suppression and monitoring
- Food, alcohol and the limits of liver supplements
- HBsAg, anti-HBs and anti-HBc: why a panel matters
- Jaundice, bleeding and severe-illness warnings
- Immune suppression, hepatitis C treatment and reactivation
- Pregnancy, newborns, children and exposure precautions
- The results, prevention and follow-up plan
- Laboratory antiviral effects versus human clinical outcomes
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
| Question | Evidence role | Interpretation / confidence |
|---|---|---|
| Can HBV be present without symptoms? | Clinical education and testing guidance | Yes. Symptoms cannot establish infection status or treatment need. |
| Does every positive antibody mean active HBV? | Original test interpretation | No. The full combination and clinical history matter. |
| What does chronic care involve? | Attributed clinical framework | Assessment, continuing monitoring and selected antiviral treatment; no personal eligibility algorithm here. |
| Does resolved infection remove every future concern? | Reactivation precautions | No. The history can matter before immune suppression or HCV treatment. |
| Is prevention a treatment for established chronic infection? | Separate clinical purposes | No. Vaccination and selected exposure prophylaxis have preventive roles. |
Confidence is good in the virus distinctions, testing roles and urgency of the precautions described. Treatment statements explain attributed clinical care; they are not a newly conducted systematic review or financially cleared numerical efficacy ranking. An independently verified supplement replacement was not established. Public funding does not make every underlying drug or vaccine trial independent.
Acute hepatitis B, chronic infection and silent disease
Hepatitis means liver inflammation; HBV is one specific cause. Acute infection describes the early illness, while chronic infection persists. The current NHS page describes infection lasting longer than six months as chronic. The category is determined by the clinical and laboratory history, rather than the day someone first notices tiredness. Acute and chronic definitions.
Some people have fatigue, nausea, appetite loss, abdominal discomfort, dark urine, pale stool or jaundice. Others have no noticeable symptoms. Children can also have little apparent illness. A mild initial episode does not settle whether infection persists; feeling better cannot substitute for the planned results review. Symptom limits.
Persistent infection can contribute to fibrosis, cirrhosis, liver failure or liver cancer. Assessment asks what is happening now and which complications require surveillance. The absence of pain, jaundice or another dramatic symptom does not show that monitoring is unnecessary. Complication and assessment context.
Blood, body-fluid and birth-related transmission
HBV can spread through infected blood and certain body fluids, including during birth. Relevant exposures can include shared injecting equipment, sexual contact, a contaminated sharp or personal items that carry blood. Tell the clinician about the actual contact; a risk label alone does not establish whether transmission occurred. Current transmission context.
Ordinary social contact is different from blood or relevant body-fluid exposure. Sharing a meal, hugging or being coughed on is not the transmission route described in the NIDDK original. A diagnosis should prompt informed prevention and contact advice, rather than excluding someone from routine social life. Transmission distinctions.
Age at infection and immune circumstances affect the likelihood of persistent disease. The December 2024 educational source explains why infection acquired in infancy or childhood deserves particular attention. Its population percentages are not used to predict the outcome of an individual child or adult. Age and immune context.
Supportive care, antiviral suppression and monitoring
The CDC care framework distinguishes supportive management for most acute illness from the assessment of chronic HBV. Severe illness may need hospital care. A chronic diagnosis calls for a clinician experienced in hepatitis B; not everyone with the same diagnosis needs the same medicine immediately. Attributed care framework.
Antiviral treatment can suppress viral activity and is used alongside monitoring and assessment of liver disease. Explainable treatment goals matter: ask whether the immediate purpose is viral suppression, prevention of reactivation, pregnancy-related protection or care for existing liver disease. This article does not calculate a personal treatment threshold or rank brands. Antiviral and monitoring roles.
Keep prescribed treatment and follow-up coordinated. Do not stop an HBV antiviral because symptoms settle or an online discussion calls the infection inactive. NIDDK specifically advises discussing withdrawal with the treating professional. Viral results, liver tests and the reason for treatment need to be reviewed together. Treatment-continuity precaution.
Liver-cancer surveillance and management of cirrhosis are separate components where indicated. An antiviral prescription does not remove every complication or replace all further checks. Ask which service will arrange the relevant blood tests and imaging, and who will explain an abnormal result. Continuing care.
Food, alcohol and the limits of liver supplements
Discuss suitable food, weight-related health concerns, activity and alcohol with the care team. These steps address overall liver health; they do not establish that an infection has cleared. General advice must account for any other cardiac, kidney or liver condition rather than supply a fixed fluid or exercise prescription. General supportive health context.
Alcohol can add to liver injury. Ask for help if avoiding it is difficult, rather than hiding intake from the clinical history. Tell the clinician or pharmacist about prescription medicines, nonprescription products and herbal mixtures before adding a claimed liver remedy. Alcohol and product-review precautions.
No independently verified supplement replacement for HBV prevention, antiviral care or monitoring was established in this review. That is not a claim that every conceivable product has been tested and failed. Replacing a documented nutritional deficiency is a different purpose from claiming to suppress the virus.
HBsAg, anti-HBs and anti-HBc: why a panel matters
The August 2026 CDC testing original describes a triple panel: hepatitis B surface antigen (HBsAg), surface antibody (anti-HBs) and total core antibody (anti-HBc). They are different markers. A single word such as positive, immune or antibody is not enough to interpret the full report. Original panel and interpretation.
Surface antibody may reflect vaccination or previous infection; core antibody relates to previous or ongoing natural infection rather than vaccination alone. An isolated core-antibody result has several possible explanations. Appropriate follow-up depends on the combination, vaccination record and clinical circumstances; do not diagnose yourself from one abbreviation. Selected marker distinctions.
The CDC source also discusses IgM core antibody in suspected acute infection and notes that it can occur during a severe flare or reactivation. This prevents treating one result as a universal rule about when infection began. Bring the complete report and earlier results to the consultation. Acute-testing caveat.
HBV DNA and liver assessment answer additional questions about viral activity and liver condition. Elastography, imaging or occasionally biopsy can have different purposes. Ask what uncertainty a proposed test is meant to resolve, rather than assuming a normal enzyme result answers every question. Additional assessment roles.
Jaundice, bleeding and severe-illness warnings
New yellow eyes or skin needs urgent assessment. Jaundice has causes other than HBV, and a previous positive result does not identify the reason for a new episode automatically. Explain the hepatitis history while arranging help. Urgent jaundice advice.
Vomiting blood or coffee-ground material needs medical help. Bleeding with faintness, confusion, black stool or feeling generally unwell needs emergency assessment. Do not drive yourself or treat it as a routine antiviral side effect. Bleeding and emergency triage.
Poor intake, reduced urination or persistent dizziness needs prompt advice. Confusion, severe breathing difficulty or being difficult to wake can signal an emergency. Report the symptoms and medicines; an online guide cannot determine whether the cause is liver disease, dehydration or another serious problem. Current deterioration warnings.
The chosen antiviral or preventive product has its own adverse effects, contraindications and monitoring requirements. Discuss the actual formulation and health history. The older educational description of medicine side effects as extremely rare is not used as blanket reassurance here.
Immune suppression, hepatitis C treatment and reactivation
Tell the team about current or previous HBV before chemotherapy, an immune-suppressing medicine or transplantation care. Reactivation can occur after an earlier infection and can cause serious liver injury. Testing, preventive treatment or monitoring may be needed; the exact plan belongs to the treating services. Original reactivation context.
Hepatitis C direct-acting antiviral treatment can also require HBV testing and a reactivation plan. The CDC B care source describes this precaution. Treating one virus is not a reason to disregard another positive or historical result. Make sure the hepatitis services share the relevant history. HBV/HCV treatment precaution.
Bring the complete medicine and supplement list to review, including any HIV medicines. NIDDK identifies changes involving some HIV treatments among reactivation concerns. Do not infer a stop rule from that warning; ask how the existing diagnoses and prescriptions should be coordinated. Medicine-review scope.
Pregnancy, newborns, children and exposure precautions
Pregnancy needs a coordinated plan for the pregnant person and newborn. Assessment of the maternal infection informs possible treatment, and timely infant prevention after birth has its own role. Tell the maternity and liver teams in advance; do not leave communication until symptoms appear. Attributed perinatal planning.
Newborn vaccination and selected immune-globulin protection require local clinical arrangements. Children, dialysis patients and people with impaired immunity may have different testing or prevention needs. This guide does not export a US or UK dose schedule, antibody cutoff or treatment rule worldwide. Special-population testing context.
After a possible blood or body-fluid exposure, seek advice promptly even if you feel well. CDC guidance describes assessing vaccination and, in selected circumstances, immune globulin as soon as possible. Do not wait for symptoms or use a later testing appointment as a reason to miss prevention advice. Prompt exposure prevention.
The results, prevention and follow-up plan
Ask the clinical team to explain infection status, vaccine history, the next tests, treatment purpose and the contact route for a new problem. Keep copies of the full laboratory and medicine records. A clear plan is particularly useful when different clinicians manage liver disease, pregnancy or immune treatment.
Discuss testing and protection for relevant contacts without assuming everyone needs identical care. Avoid sharing injecting equipment or blood-contaminated personal items, and tell healthcare professionals about the diagnosis. Do not make a donation decision from this guide; disclose infection and follow the relevant service rules. Contact and blood-exposure precautions.
Agree who will review the virus and liver results, arrange surveillance if indicated and follow up a missed appointment or medicine problem. This article supplies no personal antiviral dose, vaccine schedule, test cutoff, fluid amount or point at which monitoring can safely stop. Continuing specialist-care role.
Laboratory antiviral effects versus human clinical outcomes
Laboratory viral-suppression findings can inform research but cannot establish a personal antiviral choice, durable clinical benefit or safe supplement treatment. Useful human studies must distinguish viral markers from liver complications and assess harms over suitable follow-up. Manufacturer-funded or supplied-product efficacy is excluded from the independent verdict; public education does not clear every underlying trial.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 12 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
The illness has no corporate owner or manufacturing country. Pharmaceutical and vaccine manufacturers, diagnostic suppliers, care providers and supplement sellers can earn income around prevention, diagnosis and treatment. The source audit below separates institutional income, permitted gift routes, outside-reviewer interests and original treatment evidence. Unknown allocation remains unknown; an interest is not an allegation of improper conduct.
A funding tier measures proximity to the subject; a credibility grade reflects transparency and accuracy incentives. Tier4 producer or commercially supported efficacy is excluded from an independent benefit verdict even when a source is free. Separate2025–2026 disclosures do not establish payments for a December2024 NIDDK page. The infographic summarises these disclosed relationships; it does not invent proportions of a page budget.
| Source | Funding / backers | Country / jurisdiction | Independence / credibility / gaps | Role in this article |
|---|---|---|---|---|
| NIDDK hepatitis B, December 2024 | US NIH/HHS federal research institute: Congressional appropriations and permitted voluntary conditional/unconditional gifts and bequests; actual FAQ. The original budget table reports about $2.33 billion FY2026 enacted institutional funding, kept separate from the FY2027 request. This is not the hepatitis/page budget. Actual gift donors and page allocation unclosed. Credited outside reviewer: Anna Lok (University of Michigan): 2025 original guideline declarations lists Novo Nordisk monitoring-board and multiple drug-company consultancy roles. These separate declarations do not prove a company funded the December2024 NIDDK page; contemporaneous page compensation and original trial funds are unclosed. | United States federal education, Bethesda; credited reviewer location: Ann Arbor, Michigan, United States; University of Michigan. Local clinical and vaccine policies differ. | Tier 3 for relevant commercially connected outside reviewers; public institution separately identified. C provisional — actual December2024 patient original checked for selected definitions, testing or care roles. Public educational accountability supports accuracy; simplification, credited reviewer interests and unclosed contemporaneous/trial finance limit independent efficacy use. No numerical treatment ranking or obsolete approval claim adopted. | Acute/chronic definitions, liver assessment and reactivation; credited reviewer identified |
| NHS hepatitis B, November 17, 2025 | The national NHS website states DHSC funding and no advertising or corporate sponsorship in its content policy. Policy text is dated October2022; institutional arrangements can change. Complete page-author declarations and underlying treatment-trial finances were not supplied. Hospital trusts have separate income. | United Kingdom; national NHS England education. Use equivalent local urgent/emergency services outside the UK. | Tier 1 public education provisional; author and original treatment-trial finance unclassified. B provisional — actual dated national original checked for the attributed definitions, precautions or warning signs. Public accountability supports accuracy; simplified wording and complete individual/trial financial chain remain unclosed. | Transmission, symptom limits, chronic care and pregnancy context |
| CDC hepatitis B clinical care, January 31, 2025 | US CDC/HHS public budget authority and transfers. The FY2026 operating plan lists $46 million for the whole viral-hepatitis programme, not this page or a specific trial. Separate gift policy permits direct gifts, in-kind support and CDC Foundation transfers with conflict review. Actual page donors, reviewers and trial allocations remain unresolved. | United States; CDC Division of Viral Hepatitis, Atlanta; US clinical/public-health policy. | Tier 1 public education provisionally; original trial and individual contributor chains unclassified. B provisional — dated original body actually read. Public-health accuracy incentive, identifiable policy remit and source links; no complete author/donor/trial clearance. Brand comparisons, efficacy percentages, doses and worldwide schedule rules excluded. | Supportive versus chronic antiviral care, exposure prevention and HBV/HCV precautions |
| CDC hepatitis B testing, August 14, 2026 | US CDC/HHS public budget authority and transfers. The FY2026 operating plan lists $46 million for the whole viral-hepatitis programme, not this page or a specific trial. Separate gift policy permits direct gifts, in-kind support and CDC Foundation transfers with conflict review. Actual page donors, reviewers and trial allocations remain unresolved. | United States; CDC Division of Viral Hepatitis, Atlanta; US clinical/public-health policy. | Tier 1 public education provisionally; original trial and individual contributor chains unclassified. B provisional — dated original body actually read. Public-health accuracy incentive, identifiable policy remit and source links; no complete author/donor/trial clearance. Brand comparisons, efficacy percentages, doses and worldwide schedule rules excluded. | Triple-panel roles, complex antibody interpretation and linkage to care |
| NHS jaundice, January 22, 2024 | The national NHS website states DHSC funding and no advertising or corporate sponsorship in its content policy. Policy text is dated October2022; institutional arrangements can change. Complete page-author declarations and underlying treatment-trial finances were not supplied. Hospital trusts have separate income. | United Kingdom; national NHS England education. Use equivalent local urgent/emergency services outside the UK. | Tier 1 public education provisional; author and original treatment-trial finance unclassified. B provisional — actual dated national original checked for the attributed definitions, precautions or warning signs. Public accountability supports accuracy; simplified wording and complete individual/trial financial chain remain unclosed. | Urgent assessment of new yellow eyes or skin |
| NHS vomiting blood, August 18, 2025 | The national NHS website states DHSC funding and no advertising or corporate sponsorship in its content policy. Policy text is dated October2022; institutional arrangements can change. Complete page-author declarations and underlying treatment-trial finances were not supplied. Hospital trusts have separate income. | United Kingdom; national NHS England education. Use equivalent local urgent/emergency services outside the UK. | Tier 1 public education provisional; author and original treatment-trial finance unclassified. B provisional — actual dated national original checked for the attributed definitions, precautions or warning signs. Public accountability supports accuracy; simplified wording and complete individual/trial financial chain remain unclosed. | Bleeding triage and emergency signs |
| NHS dehydration, May 1, 2026 | The national NHS website states DHSC funding and no advertising or corporate sponsorship in its content policy. Policy text is dated October2022; institutional arrangements can change. Complete page-author declarations and underlying treatment-trial finances were not supplied. Hospital trusts have separate income. | United Kingdom; national NHS England education. Use equivalent local urgent/emergency services outside the UK. | Tier 1 public education provisional; author and original treatment-trial finance unclassified. B provisional — actual dated national original checked for the attributed definitions, precautions or warning signs. Public accountability supports accuracy; simplified wording and complete individual/trial financial chain remain unclosed. | Poor-intake and emergency warning signs |
| NIDDK actual funding, gifts and location FAQ, May2024 | US NIH/HHS federal research institute: Congressional appropriations and permitted voluntary conditional/unconditional gifts and bequests; actual FAQ. The original budget table reports about $2.33 billion FY2026 enacted institutional funding, kept separate from the FY2027 request. This is not the hepatitis/page budget. Actual gift donors and page allocation unclosed. | United States; NIH/NIDDK, Bethesda, Maryland, with a Phoenix research branch; federal jurisdiction. | Tier 3 institutional financial self-disclosure. B provisional for actual appropriations, gift and location facts. FAQ/index review May2024; actual21-page FY2027 justification printedNIDDK-6/8 separately labels FY2026 enacted, with mandatory type1-diabetes shown separately. The FY2027 request is not enacted finance; actual donors and page allocations unclosed. | Institutional provenance, not actual donor allocation |
| NIDDK budget/legislative index, May2024 review, newer requests listed | US NIH/HHS federal research institute: Congressional appropriations and permitted voluntary conditional/unconditional gifts and bequests; actual FAQ. The original budget table reports about $2.33 billion FY2026 enacted institutional funding, kept separate from the FY2027 request. This is not the hepatitis/page budget. Actual gift donors and page allocation unclosed. | United States; NIH/NIDDK, Bethesda, Maryland, with a Phoenix research branch; federal jurisdiction. | Tier 3 institutional financial self-disclosure. B provisional for actual appropriations, gift and location facts. FAQ/index review May2024; actual21-page FY2027 justification printedNIDDK-6/8 separately labels FY2026 enacted, with mandatory type1-diabetes shown separately. The FY2027 request is not enacted finance; actual donors and page allocations unclosed. | Proposals distinguished from actual appropriations |
| NIDDK actual FY2027 justification,21pages, containing separate FY2026 enacted table | US NIH/HHS federal research institute: Congressional appropriations and permitted voluntary conditional/unconditional gifts and bequests; actual FAQ. The original budget table reports about $2.33 billion FY2026 enacted institutional funding, kept separate from the FY2027 request. This is not the hepatitis/page budget. Actual gift donors and page allocation unclosed. | United States; NIH/NIDDK, Bethesda, Maryland, with a Phoenix research branch; federal jurisdiction. | Tier 3 institutional financial self-disclosure. B provisional for actual appropriations, gift and location facts. FAQ/index review May2024; actual21-page FY2027 justification printedNIDDK-6/8 separately labels FY2026 enacted, with mandatory type1-diabetes shown separately. The FY2027 request is not enacted finance; actual donors and page allocations unclosed. | Institutional enacted funding, not hepatitis/page allocation; FY2027 request kept separate |
| NHS national website content and funding policy, October2022 | The national NHS website states DHSC funding and no advertising or corporate sponsorship in its content policy. Policy text is dated October2022; institutional arrangements can change. Complete page-author declarations and underlying treatment-trial finances were not supplied. Hospital trusts have separate income. | United Kingdom; national England patient-information service. | Tier 3 editorial/funding self-disclosure. B provisional — explicit funding and disclosure policy actually read. Dated2022 policy, actual individual declarations and implementation not audited. | National website editorial/financial provenance |
| CDC actual FY2026 operating plan,4pages | US CDC/HHS public budget authority and transfers. The FY2026 operating plan lists $46 million for the whole viral-hepatitis programme, not this page or a specific trial. Separate gift policy permits direct gifts, in-kind support and CDC Foundation transfers with conflict review. Actual page donors, reviewers and trial allocations remain unresolved. | United States; Centers for Disease Control and Prevention, Atlanta, Georgia; federal jurisdiction. | Tier 3 financial, policy or contact self-disclosure. B provisional for actual original finance routes. Gift policy effective2016, reviewed2022; permission and conflict rules do not verify actual gifts, implementation or page allocations. | Whole programme budget, not a page/trial allocation |
| CDC original gift policy, effective2016; reviewed2022,24pages | US CDC/HHS public budget authority and transfers. The FY2026 operating plan lists $46 million for the whole viral-hepatitis programme, not this page or a specific trial. Separate gift policy permits direct gifts, in-kind support and CDC Foundation transfers with conflict review. Actual page donors, reviewers and trial allocations remain unresolved. | United States; Centers for Disease Control and Prevention, Atlanta, Georgia; federal jurisdiction. | Tier 3 financial, policy or contact self-disclosure. B provisional for actual original finance routes. Gift policy effective2016, reviewed2022; permission and conflict rules do not verify actual gifts, implementation or page allocations. | Direct gifts, foundation transfers and conflict-review requirements |
| CDC actual public-site contact/provenance | US CDC/HHS public budget authority and transfers. The FY2026 operating plan lists $46 million for the whole viral-hepatitis programme, not this page or a specific trial. Separate gift policy permits direct gifts, in-kind support and CDC Foundation transfers with conflict review. Actual page donors, reviewers and trial allocations remain unresolved. | United States; Centers for Disease Control and Prevention, Atlanta, Georgia; federal jurisdiction. | Tier 3 financial, policy or contact self-disclosure. B provisional for actual original finance routes. Gift policy effective2016, reviewed2022; permission and conflict rules do not verify actual gifts, implementation or page allocations. | Atlanta institutional location |
| Lok/Feld original 2025 guideline financial declarations, 45 pages | Actual 2025 AASLD/IDSA guideline accepted-manuscript pages3–4 lists Lok’s monitoring-board/consultancy and Feld’s drug-company consultancy. A draft disclosure placeholder remains elsewhere. Society income, complete original trial funding and the December2024 NIDDK review compensation unclosed. | United States-led guideline with Canadian author affiliations; IDSA-hosted original, DOI10.1097/HEP.0000000000001549. | Tier 3 financially connected authors and direct disclosure. B provisional for selected explicit financial declarations only; full clinical guidance not adopted here. Accepted-manuscript presentation and incomplete funding chain remain visible. | Separate credited-reviewer interests only; no attribution to the December 2024 patient page |
Frequently asked questions
Can I have HBV while feeling well?
Yes. Testing and follow-up cannot be replaced by symptoms.
Does a positive antibody mean I have active infection?
Not automatically. The full marker combination and history matter.
Does chronic HBV always require an immediate prescription?
No. The specialist assesses viral activity, liver disease and the clinical circumstances.
Can an old infection matter before chemotherapy?
Yes. Tell the team so reactivation risk can be assessed.
Should a possible exposure wait until symptoms start?
No. Seek prompt local prevention advice.
Does a liver supplement replace antiviral monitoring?
No independently verified replacement is established here.
Sources and funding notes
- NIDDK hepatitis B, December 2024 — Acute/chronic definitions, liver assessment and reactivation; credited reviewer identified.
- NHS hepatitis B, November 17, 2025 — Transmission, symptom limits, chronic care and pregnancy context.
- CDC hepatitis B clinical care, January 31, 2025 — Supportive versus chronic antiviral care, exposure prevention and HBV/HCV precautions.
- CDC hepatitis B testing, August 14, 2026 — Triple-panel roles, complex antibody interpretation and linkage to care.
- NHS jaundice, January 22, 2024 — Urgent assessment of new yellow eyes or skin.
- NHS vomiting blood, August 18, 2025 — Bleeding triage and emergency signs.
- NHS dehydration, May 1, 2026 — Poor-intake and emergency warning signs.
- NIDDK actual funding, gifts and location FAQ, May2024 — Institutional provenance, not actual donor allocation.
- NIDDK budget/legislative index, May2024 review, newer requests listed — Proposals distinguished from actual appropriations.
- NIDDK actual FY2027 justification,21pages, containing separate FY2026 enacted table — Institutional enacted funding, not hepatitis/page allocation; FY2027 request kept separate.
- NHS national website content and funding policy, October2022 — National website editorial/financial provenance.
- CDC actual FY2026 operating plan,4pages — Whole programme budget, not a page/trial allocation.
- CDC original gift policy, effective2016; reviewed2022,24pages — Direct gifts, foundation transfers and conflict-review requirements.
- CDC actual public-site contact/provenance — Atlanta institutional location.
- Lok/Feld original 2025 guideline financial declarations, 45 pages — Separate credited-reviewer interests only; no attribution to the December 2024 patient page.
Actual December 2024 NIDDK, November 2025 NHS, January 2025 CDC care and August 2026 CDC testing bodies were read. The testing page’s erroneous wording calling core antibody an antigen is not copied. Fixed vaccine schedules, numeric treatment thresholds, older extremely-rare-side-effect reassurance, current worldwide drug-status claims and original-trial efficacy percentages are excluded. Lok’s separate 2025 declaration is not assigned as a payment for the December 2024 page. Current primary patient guidance and the selected financial originals were read. Complete original treatment trials, their suppliers, society ownership/backer chains and contemporaneous page-review compensation were not audited. No personal dose, brand hierarchy or trial benefit percentage is supplied. ClinicalTrials.gov listings, institutional names and accreditation do not themselves establish safety or independence.
Last reviewed: October 4, 2026. Educational information, not a diagnosis or personal treatment plan. Use your local emergency service for an emergency.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.